TOLMAR Pharmaceuticals, Inc.
475 Half Day Road
About TOLMAR Pharmaceuticals, Inc.TOLMAR Pharmaceuticals' US commercial business is based in Lincolnshire, Illinois, with TOLMAR global headquarters, product development, and manufacturing facilities based in Northern Colorado.
CEO: Susan Rodriguez
Please click here for TOLMAR Pharma job opportunities.
8 articles with TOLMAR Pharmaceuticals, Inc.
Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®- Tolmar’s 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists -
Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote ALKINDI SPRINKLE®.
Tolmar Publishes FENSOLVI ® (leuprolide acetate) for Injectable Suspension Safety and Efficacy Data in Journal of Clinical Endocrinology and Metabolism
Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced the publication of an open-label, single arm, multicenter Phase 3 study on the efficacy, safety, and pharmacokinetics of Fensolvi® (leuprolide acetate) for injectable suspension for patients with Central Precocious Puberty.
Tolmar Affirms Supply of FENSOLVI® (leuprolide acetate) for Pediatric Patients with Central Precocious Puberty
Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, today affirmed the full availability of FENSOLVI® (leuprolide acetate) for injectable suspension in its six-month dose (45mg) for pediatric patients with central precocious puberty (CPP)
Tolmar Affirms Full Supply of Eligard® (Leuprolide Acetate) for Injectable Suspension for the Palliative Management of Advanced Prostate Cancer
Company increases manufacturing capacity of U.S.-made drug to ensure uninterrupted supply for patients undergoing treatment amid industry shortage
Real-World Data Analysis Published in the Journal of Urology Explores Frequency of Late Luteinizing Hormone-Releasing Hormone Agonist (LHRH) Dosing and Impact on Testosterone Suppression in Patients with Prostate Cancer
Data demonstrate that late dosing results in failure to maintain testosterone suppression to recommended levels for disease management
FDA Approves FENSOLVI® (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty
Fensolvi is the only six-month, subcutaneously administered leuprolide acetate approved for the treatment of pediatric patients two years of age and older with Central Precocious Puberty
Tolmar Pharmaceuticals Sponsors 2018 ZERO - The End of Prostate Cancer Endurance Team at the Bank of America Chicago Marathon
TOLMAR Pharmaceuticals, Inc. today announced its exclusive sponsorship of ZERO - The End of Prostate Cancer's (ZERO) Endurance Team at the 2018 Bank of America Chicago Marathon.
Data From TOLMAR Pharma On ELIGARD Demonstrate Serum Leuprolide Levels Required To Maintain Stable, Long-Term Testosterone Suppression Across All Doses